The Spectranetics CorporationNASDAQ
Advanced Chart
  • Nov. 28, 2014, 10:45 AM
    | Nov. 28, 2014, 10:45 AM
  • Nov. 26, 2014, 3:57 PM
    • The Federal Trade Commission approves the merger between Medtronic (MDT +1%) and Covidien plc (COV +1.2%) with the proviso that Covidien divest its drug-coated catheter business before completing the transaction. Covidien agreed to sell the business for $30M to Spectranetics (SPNC +1%) several weeks ago.
    • Previously: Medtronic buying Covidien for $42.9B
    | Nov. 26, 2014, 3:57 PM
  • Nov. 3, 2014, 8:11 AM
    • Spectranetics (NASDAQ:SPNC) acquires Covidien's (NYSE:COV) Stellarex drug coated angioplasty balloon (DCB) platform for $30M. The company expects it to be a revenue catalyst beginning in 2015 and has the potential to deliver $100M to the top line within 2-3 years of commercialization in the U.S. Management expects it to be accretive to non-GAAP operating income, ex-items, in the first year following the start of the U.S. launch.
    • Research and development related to Stellarex will dilute 2015 earnings $28M - 32M or $0.65 - 0.75 per share, however.
    | Nov. 3, 2014, 8:11 AM
  • May 27, 2014, 6:53 PM
    • Spectranetics (SPNC) is buying AngioScore, a maker of cardiovascular balloons, for $230M up-front ($115M apiece in cash and stock), plus contingent commercial/regulatory milestone payments.
    • The deal, which broadens Spectranetics' product line, is expected to close around the end of June. Spectrnetics expects it to be accretive to 2015 adjusted EBITDA, and to yield $8M-$10M in pre-tax cost synergies.
    • To help pay for the acquisition, Spectranetics is selling $200M worth of convertible senior notes due 2034. The underwriter will have a $30M overallotment option.
    | May 27, 2014, 6:53 PM